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The arrival of a true point-of-care molecular assay—ready for 
global implementation?
The arrival of the next generation of advanced diagnostic 
point-of-care tests was announced on July 28, 2015, when 
Cepheid and their non-proﬁ t partner, FIND, unveiled 
a new device called GeneXpert Omni.1  Although this 
device might seem to be yet another rapid nucleic acid 
ampliﬁ cation test, it is small (23 cm tall), lightweight 
(1 kg), easy to use, powered by a rechargeable battery, and 
has wireless connectivity, making it the ﬁ rst true point-
of-care molecular assay. This portable device will allow 
health-care workers to do sophisticated molecular testing 
in the most remote areas of the world. Since it operates all 
the same PCR-based cartridge tests as Cepheid’s existing 
GeneXpert, it is already capable of performing multiple 
diagnostic tests, including tests for tuberculosis, drug-
resistant tuberculosis, HIV, and Ebola virus.
GeneXpert Omni builds on the global successes of ﬁ rst-
generation diagnostic point-of-care tests and Cepheid’s 
laboratory-based GeneXpert system.2 These ﬁ rst-
generation tests are straightforward assays to indicate 
the presence (or amount) of a molecule or an antigen on 
a strip of paper,3 and they have substantially improved 
the management and diagnosis of important conditions 
and diseases. For example, millions of patients with 
diabetes worldwide optimise their blood sugar level by 
inserting a blood-saturated strip of paper into a small, 
battery-powered glucometer;4 women collectively use 
roughly 300 000 urine tests per day in the comfort of 
their home to know their pregnancy status;5 and rapid 
HIV tests have helped 600 million adults to know their 
HIV serostatus in 122 low-income and middle-income 
countries in 2010–14.6
Cepheid’s GeneXpert system achieved recognition 
as a rapid molecular test to identify active tuberculosis 
and rifampicin resistance, a marker for multidrug-
resistant tuberculosis.7 So far, more than 13 million 
Xpert Mycobacterium tuberculosis/rifampicin (MTB/RIF) 
tests have been done worldwide.1 However, the primary 
criticism has been that implementation of rapid 
GeneXpert testing in reference laboratories has had 
little eﬀ ect on reaching the 3 million individuals with 
M tuberculosis infection who remain undiagnosed 
each year.8 What had been lacking, until now, was an 
accurate, portable device to allow health-care workers 
to actively identify infected patients in the community, 
thereby breaking the cycle of tuberculosis transmission.
GeneXpert was designed to identify several infectious 
organisms and genetic biomarkers, and the machines 
are operating in laboratories around the world. The 
system can already identify eight hospital-associated 
infections, 12 additional infectious diseases, and 
genetic markers for cancer (BCR–ABL) and thrombosis 
risk (Factors II and V), with several more tests in 
development.9 By using the same platform, the portable 
Omni gives health-care workers the ability to do all the 
same cartridge-based tests in the community.
Although the ability to do advanced nucleic acid 
testing in remote, resource-limited settings could 
change the approach to global health delivery, discussion 
of the potential challenges is needed before widespread 
implementation. First, an agreement must be reached 
about regulatory assurances and quality control 
measures to ensure oversight for maintenance of the 
integrity and accuracy of diagnostic testing. Although 
GeneXpert Omni has wireless connectivity for remote 
result monitoring, who will be responsible for such a task 
is unclear. Second, in view of the existing global shortage 
of laboratory expertise,10 there is little understanding 
of whether community-based testing might place an 
additional strain on laboratory systems by requiring 
Figure: Estimated annual research and global market for point-of-care diagnostics
The annual number of citations was determined by a customised search in the PubMed database for the term 
“point-of-care test”. The estimated global market data were provided by Visiongain.11
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more staﬀ  resources and logistical support, or whether 
eﬀ ective point-of-care testing could help to oﬄ  oad some 
of the burden on laboratory workers. Third, no clear 
guidance exists to help stakeholders to decide on the 
adoption of novel point-of-care tests. Should each new 
device or test be required to show greater accessibility to 
testing or better patient outcomes than existing ones? If 
so, then each device or test might need to be assessed in 
clinical implementation trials and analysed for its cost-
eﬀ ectiveness, which will be time consuming and costly.
These are just some of the topics that will need an open 
discussion between public health oﬃ  cials, hospital and 
clinic administrators, laboratory managers, clinicians, 
and outreach workers. GeneXpert Omni has set a new bar 
for true point-of-care molecular assays and opened the 
door for a range of applications, from improved contact 
tracing for infectious diseases to community-based 
screening for certain cancers. The global research and 
market for diagnostic point-of-care tests will continue to 
grow rapidly over the coming years (ﬁ gure).11 However, 
for these tests to have a positive eﬀ ect, dialogue among 
the various stakeholders should begin now.
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